The evidence suggested that berberine consumed EGFR and ERBB2 in ovarian cancer cells and inhibited the activation of EGFR and ERBB2 downstream targets cyclin D1, MMPs, and VEGF via the EGFR-ERBB2/PI3K/Akt signaling pathway [100]. The gene discussed is EGFR; the disease is ovarian cancer.